Evidence map›Paper›PMID 27667685›Full record

ArticleCell2016

A Functional Role for Antibodies in Tuberculosis.

Lenette L Lu, Amy W Chung, Tracy R Rosebrock, Musie Ghebremichael, Wen Han Yu, Patricia S Grace, Matthew K Schoen, Fikadu Tafesse, Constance Martin, Vivian Leung and 15 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 385 papers.

0numbers the graph read from it
0cells of the map it votes in
385citing papers in PubMed
50.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

385 citing papers in PubMed, 565 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Tuberculosis treatment and cytotoxic immune signatures: a longitudinal study.Journal of clinical tuberculosis and other mycobacterial diseases · 2026
    Article
  10. Article
  11. Review
  12. Glycosylation profile ofiScience · 2026
    Article
  13. Review
  14. Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. HowVaccines · 2026
    Review
  20. Article

325 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 8 institutions in 5 countries.

Lenette L LuRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA; Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA 02115, USA.
Amy W ChungRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA; Department of Microbiology and Immunology, Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.
Tracy R RosebrockDepartment of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA 02115, USA.
Musie GhebremichaelRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Wen Han YuRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
Patricia S GraceRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Matthew K SchoenRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Fikadu TafesseRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Constance MartinDepartment of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA 02115, USA.
Vivian LeungDepartment of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA 02115, USA.
Alison E MahanRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Magdalena SipsRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA; Department of Biomedical Molecular Biology, Ghent University, Ghent 9000, Belgium.
Manu P KumarDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
Jacquelynne TedescoRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Hannah RobinsonRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Elizabeth TkachenkoRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Monia DraghiRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Katherine J FreedbergRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Hendrik StreeckInstitute for Medical Biology, University Hospital Essen, University of Duisburg-Essen, 45141 Essen, Germany.
Todd J SuscovichRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Douglas A LauffenburgerDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
Blanca I RestrepoSchool of Public Health, University of Texas Health Houston, Brownsville, TX 78520, USA.
Cheryl DayEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30307, USA; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30332, USA; South African Tuberculosis Vaccine Initiative (SATVI) and School of Child and Adolescent Health, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Observatory, Cape Town 7925, South Africa.
Sarah M FortuneDepartment of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA 02115, USA. Electronic address: sfortune@hsph.harvard.edu.
Galit AlterRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA. Electronic address: galter@mgh.harvard.edu.
Ragon Institute of MGH, MIT and Harvard · USHarvard University · USMassachusetts Institute of Technology · USGhent University · BEPeter Doherty Institute · AUSouth African Tuberculosis Vaccine Initiative · ZAThe University of Texas Health Science Center at Houston · USUniversity of Duisburg-Essen · DE

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
Multidisciplinary HIV Training ProgramT32AI007387 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel R. Kuritzkes · 1990 to 2026
$8.8M
Demystifying the antiviral activity of the IgG3+ antibody responseR01AI080289 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI JUELG, BORIS DOMINIK · 2009 to 2024
$4.1M
Tuning Fc-effector functions of HIV-specific antibodiesR01AI102660 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI ALTER, GALIT · 2012 to 2015
$3.0M
Mechanisms of Immune Regulation in Mycobacterium Tuberculosis InfectionR01AI083156 · NIAID · UNIVERSITY OF CAPE TOWN · PI DAY, CHERYL LIANE · 2009 to 2012
$415k
Doris Duke Charitable FoundationNIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI080289NIAID NIH HHS R01 AI083156NIAID NIH HHS R01 AI102660NIAID NIH HHS T32 AI007387
6 · The paper itself

Abstract

While a third of the world carries the burden of tuberculosis, disease control has been hindered by a lack of tools, including a rapid, point-of-care diagnostic and a protective vaccine. In many infectious diseases, antibodies (Abs) are powerful biomarkers and important immune mediators. However, in Mycobacterium tuberculosis (Mtb) infection, a discriminatory or protective role for humoral immunity remains unclear. Using an unbiased antibody profiling approach, we show that individuals with latent tuberculosis infection (Ltb) and active tuberculosis disease (Atb) have distinct Mtb-specific humoral responses, such that Ltb infection is associated with unique Ab Fc functional profiles, selective binding to FcγRIII, and distinct Ab glycosylation patterns. Moreover, compared to Abs from Atb, Abs from Ltb drove enhanced phagolysosomal maturation, inflammasome activation, and, most importantly, macrophage killing of intracellular Mtb. Combined, these data point to a potential role for Fc-mediated Ab effector functions, tuned via differential glycosylation, in Mtb control.

Indexed as

Immunity, HumoralAdultAntibodies, BacterialFemaleGlycosylationHost-Pathogen InteractionsHumansImmunoglobulin Fc FragmentsLatent TuberculosisMacrophage ActivationMaleMiddle AgedMycobacterium tuberculosisPolysaccharidesProtein Array AnalysisReceptors, IgGAntibodies, BacterialFCGR3A protein, humanImmunoglobulin Fc FragmentsPolysaccharidesReceptors, IgGantibodiesFc-receptorsinflammasomeinnate immunitytuberculosis

Identifiers

PMID27667685
PMCPMC5526202
OpenAlexW2521361619

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.